PSMA Emerges as Versatile Target in Prostate Cancer and Beyond

Jane De Lartigue, PhD
Published: Wednesday, Jun 19, 2019
Named the medical invention of the Year by TIME magazine at the turn of the millennium,1 positron emission tomography/ computed tomography (PET/CT) has changed the landscape of cancer diagnosis, facilitating earlier detection and more accurate staging of a range of tumor types.2

Along with magnetic resonance imaging (MRI) and bone scans, PET/CT has become a pillar of prostate cancer management, which is often challenging because of the disease’s highly varied clinical course. These imaging technologies, however, have limitations, particularly regarding the detection of disease recurrence after primary treatment.3

Investigators are looking at prostate-specific membrane antigen (PSMA), a highly prostate-restricted membrane protein, to fill the need for more sensitive imaging technologies. The possible applications of PSMA-targeted PET/CT run the gamut from initial staging to better identification of biochemical recurrence.

Accumulating evidence also suggests that it could serve as a tool to guide treatment and improve patient outcomes.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication